

GDG1: Screening, diagnostic assessment, risk assessment and life-stage

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. **Public funding sources, such as government agencies or academic institutions need**

Question	Wiebke Arit	Ricardo Aziz	Lorna Berry	Carolyn Ee	Anju Joham	Joop Laven	Ronald Ma
Research Grants / Contracts		Ferring. A comparative study between PCOS women in Nigeria and African-American women in the US. 1/1/22-12/31/22	No disclosures			Ferring: Elucidating the genetic architecture of PCOS. Current Merck: Grant for Genetics of POI current	Bayer. Support to university for conducting FIGARO DKD trial (Finerenone). 01/2016- 11/2020. Novo Nordisk. Support to university for conducting SOUL Trial (Semaglutide). 05/2019- ongoing. Support to university for conducting PIONEER 12 Trial (Semaglutide). 7/2020- 01/2022. Support to university for conducting NN-9536-4379 trial (Semaglutide). 10/2020- ongoing. Tricida Inc. Support to university for conducting VALOR-CKD trial (TRC-101). 1/2019- ongoing. Pfizer/Merck Sharp and Dohme. Support to university for conducting Vertis Trial (ertugliflozin). 2/2017-6/2020. Sanofi. Support to university for conducting ARTEMIS study (glargine-U300). 09/2019-10/2020. Roche Diagnostics (Hong Kong) Limited. Support to university for investigator initiated research project on NT-proBNP and CV risk in diabetes. 02/2022- ongoing.
Advisory boards	Bayer, Spruce (current)	Arora Forge. Health IT. 1/1/22-Present Spruce Biosciences, Fortress Technology, CAST. PCOS, adrenal hyperplasia, gyn laparoscopy. 6/15/20- Present				Ferring Rekovelle), Roche Diagnostics (AMH and PCOM), AMH cut off for PCOM in PCOS (Ansh Labs), Gedeon Richter (Ryeco GnRH and add back for Fibroids) Current	Merck, Advisory Board meeting, 10/22 Kyowa Kirin Asia Pacific Pty Ltd, Advisory Board meeting, 7/22
Consulting / Honoraria	Bayer, Spruce, OMass, Crinetics (current)					Ferring, Titus Health Care. Quality vs Quantity in ART (Ferring) Microbiome and IVF Outcome (Titus Health Care). Current	
Speakers' fees or honoraria Paid authorship					Novo Nordisk. Fees for speaking about Semaglutide. May 2022 Boehringer Ingelheim. Fees for speaking about empagliflozin. March 2020.	Ferring. Rekovelle experience in real live patients. Current.	Bayer. Speaker honorarium. 01/2021. Boehringer Ingelheim. Speaker honorarium. 10/2020
Meeting attendance /paid expenses, e.g. travel, accomm, meals					Indian Society for Assisted Reproduction. Invited speaker to the Yuva Program. Travel and accommodation provided. Some meals provided as part of conference.	ESHRE 2022. Ferring. Current.	
Intellectual Property (patents, licenses, royalties)							Holder of several patents for genetic or other molecular markers for predicting risk of diabetes or diabetic complications. Co-founder of a technology start-up to provide genetic testing based on these molecular markers.
Stock options / holdings		Martin Imaging. PET scanning. 1/1/17 - Present					
Private practice or professional income					Monash Health. Public Hospital. 2003- current. Monash University. Senior Research Fellow. 2016 - current. Private consulting. 2016 - current.		
Unpaid consultancies and/or in-kind support Family member employment/financial interests					Board member - AEPCCOS. 2021 - current.	Ferring, Roche Diagnostics. Elucidating the genetic Architecture of PCOS (Ferring) and AMH cut off for PCOM in PCOS (Roche Diagnostics) . PCOM and PCOS check (Ansh Labs) Current.	
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg. professional organization)							Hong Kong College of Physicians, Council member. Asian Association for the Study of Diabetes (AASD). Board member. Worldwide Initiative for Diabetes Education (Worldwide Diabetes), past Board Member (2017-2021) International DOHAD Society, Council member. FIGO Committee on the Impact of Pregnancy on Long-term Health, Committee member.
Relationship with organisations which advocate known industry or policy positions Relationships of immediate family members				RACGP, Endocrine Society of Australia. Fellow of RACGP; Deputy Chair of Specific Interests Council at RACGP; Chair of Integrative Medicine Specific Interests Network at RACGP; member, ESA			
Other Additional information							
Are there any disclosures requiring a management plan?	No	No	No	No	No	No	No

GDG1: Screening, diagnostic assess					
Disclose support ONLY from entities <b>not</b> be disclosed. Time period for disclosure is within 3 years from when this form is completed.					
Question	Sharon Oberfield	Malika Patel	Alexia Peña Vargas	Duru Shah	Fahimeh Ramezani Tehrani
Research Grants / Contracts	T32 DK065522-16, NIH/NIDDK		No disclosures		No disclosures
Advisory boards	Board Member: Congenital Adrenal Hyperplasia Research Education and Support Foundation (CARES)	Adcock - Zoely Advisory			
Consulting / Honoraria					
Speakers' fees or honoraria					
Paid authorship					
Meeting attendance /paid expenses, e.g. travel, accomm, meals		ESHRE 2022 Ferring: conference fees and flights			
Intellectual Property (patents, licenses, royalties)					
Stock options / holdings					
Private practice or professional income				Yes	
Unpaid consultancies and/or in-kind support					
Family member employment/financial interests					
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg, professional organization)	Immediate past president PES			Leadership in PCOS Society of India	
Relationship with organisations which advocate known industry or policy positions					
Relationships of Immediate family members				Husband- Promoter of Diagnostic Lab Chain	
Other	Member, NIH-NIDDK Study Section Review Committee (Oct 2022 - present)				
Additional information					
Are there any disclosures requiring a management plan?	No		No	No	No

GDG2: Prevalence, screening, diagnostic assessment and management of emotional wellbeing and models of care

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. **Public funding sources, such as government agencies or academic institutions need not be disclosed.** Time period for disclosure is within 3 years from when this form is completed.

[illegible]

GDG3: Lifestyle, medical and surgical management

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. [Public funding sources, such as government](#)

Question	Lorna Berry	Leah Brennan	Cheryce Harrison	Angelica Hirschberg	Kathleen Hoeger	Kate Marsh
Research Grants / Contracts	No disclosures		No disclosures	No disclosures	NICHD, Mae Stone Goode Foundation. Ovarian ultrasound and PCOS features; melatonin in PCOS; Infant development from PCOS moms. Current.	
Advisory boards					Ablacare. DSMB Ablacare. Current	
Consulting / Honoraria						
Speakers' fees or honoraria						
Paid authorship						
Meeting attendance /paid expenses, e.g. travel, accomm, meals						
Intellectual Property (patents, licenses, royalties)						
Stock options / holdings						
Private practice or professional income		Director of group private psychology practice (Centre for Eating Weight and Body Image) focused on psychological aspects of eating, weight and body image and biopsychosocial correlates.				income from private practice seeing women with PCOS, current
Unpaid consultancies and/or in-kind support						
Family member employment/financial interests						
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg, professional organization)					Membership. Endocrine Society, ASRM, ESHRE	
Relationship with organisations which advocate known industry or policy positions					President, AE-PCOS Society. Organization representing researchers in PCOS.	
Relationships of Immediate family members						
Other						
Additional information						
Are there any disclosures requiring a management plan?	No	No	No	No	No	No

GDG3: Lifestyle, medical and surgic:

Disclose support ONLY from entities not agencies or academic institutions need not be disclosed. Time period for disclosure is within 3 years from when this form is completed.

Question	Lisa Moran	Leanne Redman	Mala Thondan	Chandrika Wijeyaratne
Research Grants / Contracts	No disclosures	No disclosures	No disclosures	
Advisory boards				
Consulting / Honoraria				
Speakers' fees or honoraria				
Paid authorship				
Meeting attendance /paid expenses, e.g. travel, accomm, meals				
Intellectual Property (patents, licenses, royalties)				
Stock options / holdings				
Private practice or professional income				Personal capacity during scheduled sessions. Not related to a project. 2018-current.
Unpaid consultancies and/or in-kind support				
Family member employment/financial interests				
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg, professional organization)				
Relationship with organisations which advocate known industry or policy positions				
Relationships of Immediate family members				
Other				
Additional information				
Are there any disclosures requiring a management plan?	No	No	No	No

GDG4: Management of non-fertility features

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. Public funding sources, such as government.

Question	Jacqueline Boyle	Wendy Brown	Carolyn Ee	Rong Li	Rachel Morman	Alexia Peña Vargas
		Johnson and Johnson, bariatric surgery registry, 2018-current GDRE, bariatric surgery registry, 2014 - current Applied Medical, bariatric surgery registry, 2013-2021 Novo Nordisk, RCT tiraglutide vs control with bariatric surgery, 2018-current. Myerton, RCT on the impact of preperment of on halitosis whilst on a VLCD, current. Medtronic, bariatric surgery registry, 2014-current. NHMRC, research into fatty liver disease, an RCT of weight loss prior to knee replacement surgery and a multicentre RCT exploring the use of TKA intraoperatively Commonwealth Government, bariatric surgery registry.				
Research Grants / Contracts			As for GDG 1	No disclosures	No disclosures	No disclosures
Advisory boards		Merck Sharp and Dohme, 2021 Novo Nordisk, 2020 & 2021 Pfizer, 2020				
Consulting / Honoraria						
Speakers' fees or honoraria		Gore Medical, 2020 Merck Sharp and Dohme, 2019 & 2022				
Paid authorship						
Meeting attendance /paid expenses, e.g. travel, accomm, meals						
Intellectual Property (patents, licenses, royalties)						
Stock options / holdings						
Private practice or professional income	Private gynaecology practice	Private practice as a General Surgeon with a special interest in Upper GI and Bariatrics, ongoing				
Unpaid consultancies and/or in-kind support						
Family member employment/financial interests						
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg. professional organisations)						
Relationship with organisations which advocate known industry or policy positions	RANZCOG member of committees. VARTA advisory board.					
Relationships of immediate family members						
Other						
Additional information						
Are there any disclosures requiring a management plan?	No	No	No	No	No	No

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. **Public funding sources, such as government agencies or academic institutions need not be disclosed.** Time period for disclosure is within 3 years from when this form is completed

[illegible]

GDG5: Screening, diagnostic assessment and management of infertility.

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. **Public funding sources, such as government agencies or academic institutions need**

Question	Adam Balen	Lisa Bedson	Michael Costello	Roger Hart	Tuong Ho	Kim Hopkins	Cailin Jordan
Research Grants / Contracts					Ferring, Rekovelle. 2019-2021	No disclosures	
Advisory boards	Member advisory board on PCOS and weight reduction, NovoNordisk Pharmaceuticals.		Merck. Advice on how Merck can partner with clinicians to support clinicians and patients. 2021 -2022 Ferring. Educational advice. 2022.				
Consulting / Honoraria	NHS Consultant in Reproductive Medicine, Honorary Chair and Clinical lead for Leeds Centre for Reproductive Medicine, Leeds Teaching Hospitals NHS Trust. Consultant at CARE Fertility, Leeds, responsible for tertiary level assisted conception in Leeds. Chair of Care Fertility UK Innovation and Research Board.						
Speakers' fees or honoraria				Merck, Merck Serono, Origio. Fees for webinars. 2020-2022.	Merck, MSD, Ferring, Abbott		Merck Group. Invited speaker ASPIRE 2021: Enhancing patient engagement throughout their ART journey. May 2021.
Paid authorship	Author of The Fertility Book. A book for patients about reproductive health						
Meeting attendance /paid expenses, e.g. travel, accomm, meals		Merck. May assist with accommodation/ registration for ASRM 2022. Possibly 5 days Oct 2022.	Merck.	Organon and Gideon-Richter	Merck, MSD, Ferring, Abbott		FSA. FSA 2019 Invited speaker – How to speak to ART patients about lifestyle change. Oct 2019.
Intellectual Property (patents, licenses, royalties)							
Stock options / holdings	CARE Fertility Leeds CARE Fertility UK	Monash IVF shares. >10 years		CHA			
Private practice or professional income	Director Balance Reproductive Health Ltd: personal company for private fertility care. Partner in Balance Health Ltd, Balance Mind Ltd, Balance Fertility Ltd - private companies for the management of all aspects of reproductive health. Medicolegal work on a regular basis with approximately 50:50 for defendant and claimant.	Monash IVF/ Reprodmed. Employee of Reprodmed. 17 years +		Private consulting fees.			
Unpaid consultancies and/or in-kind support							
Family member employment/financial interests							
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg, professional organization)		Employee Monash IVF/ Reprodmed, an ART service provider.		National Medical Director, City Fertility			
Relationship with organisations which advocate known industry or policy positions	Fellows' Representative RCOG Council for Northern, Yorkshire and Humber. Member World Health Organisation Guideline Development Group on Infertility Trustee of The British Fertility Society (BFS). Member International Federation of Obstetricians and Gynecologists (FIGO) Steering Group on Anovulatory Infertility.			Chair of Ministers Expert Panel for Assisted Reproduction in Western Australia			
Relationships of Immediate family members							
Other							
Additional information							
Are there any disclosures requiring a management plan?	No	No	No	No			No



**Not to be disclosed.** Time period for disclosure is within 3 years from when this form is completed.

Richard Legro	Edgar Mocanu	Robert Norman	Luk Rombauts	Shakila Thangaratnam	Lan Vuong	Dongzi Yang
Many disclosures. Refer separate worksheet		Several NHMRC grants including member of two CREs		No disclosures	The National Foundation for Science and Technology (NAFOSTED). Oocyte in-vitro maturation. August 1 2018 to August 1 2022	The National Key Research and development Program of China(2017YFC1001004);The 5010 grants of Sun Yat-Sen University(No.SYSU2014005)
	CRYOS	Ferring educational advice 2021	Ferring, Merck. General advice. Last 3 years			
		Vinh Mec Hospital, Hanoi, Vietnam, Flinders Fertility Adelaide				
		Merck speaker 2020, Cadila Pharm 2022, Blue Oceans 2022			Speaker fees from Merck; Ferring; MSD. No specific product.	
		Fertility Society Australia (FSANZ) as congress speaker - travel and accommodation	Merck. Attendance Accom + registration ASRM 2022. 2022.			
			minority shareholder Monash IVF Group			
		Consultant REI training Flinders Fertility; Chair Clinical Advisory Committee Westmead fertility	Private practice		Private clinic outside of working hours	
		Panel for public IVF Victorian Government				
			President. FSANZ			
		Editorial Editor Fertility and Sterility	President. FSANZ			
		Member of the Robinson Research Institute, University of Adelaide				
No	No	No	No	No	No	No

**GDG5: Screening, diagnostic assessment and management of infertility.**

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. **Public funding sources, such as government agencies or academic institutions need not be disclosed.** Time period for disclosure is within 3 years from when this form is completed.

Question	Richard Legro
Research Grants / Contracts	<p>National Center for Advancing Translational Sciences. 07/01/2021 - 06/30/2026</p> <p>NIH/NCCIH. Inositol Supplementation to Treat Polycystic Ovary Syndrome: A Double-Blind Dose Ranging RCT. 09/01/2018 - 08/31/2022</p> <p>NIH/University of Pennsylvania. The COMET-PCOS Trial: Comparing the effects of Oral Contraceptive Pills versus Metformin in the medical management of overweight/obese women with PCOS. 08/01/2017 - 04/30/2022</p> <p>Guerbet USA. Therapeutic Effect of Sonographic</p> <p>Hysterosalpingography: Oil vs. Water Based Media: The SHOW Pilot Trial. 06/26/2018 -06/25/2021</p> <p>NIH/NICHD. Functional Analysis of PCOS Candidate Genes. 09/15/2016 -05/31/2021</p> <p>NIH. AMH Signaling Pathway Variation in PCOS. 06/01/2019 -02/28/2021</p> <p>Pennsylvania State University. Hass Avocado Board</p> <p>A Multi-Site Randomized Clinical Trial to Compare Healthy Eating</p> <p>Recommendations for Six Months on Changes in Visceral Adiposity in Overweight /Obese Americans (Penn State Avocado Study) 12/01/2017- 12/31/2020</p> <p>Data Coordinator Center for the RMN. 12/01/2019 -- 11/30/2020</p> <p>Penn State Clinical and Translational Science Institute. 09/15/2016 -05/31/2020.</p> <p>NIH/NICHD. Yale University Data Coordination Center for the Reproductive Medicine Network. 12/01/2017 - 11/30/2019</p> <p>Patty Brisben Foundation for Women's Sexual Health. Wright State University (Ext) Evaluation of Vitamin D with and Without Hormonal Contraception on Sexual Function in Women with PCOS. 01/01/2017 - 10/31/2019</p> <p>NIH. Cooperative Multicenter Reproductive Medicine Network 07/01/2007 - 06/30/2019</p>
Advisory boards	<p>Funded by the Research Fund, Food and Health Bureau, The Government of the Hong Kong Special Administrative Region. Advisor, A metabolomic approach to redefine diagnostic criteria and classification of polycystic ovary syndrome (PI: Professor Chi Chui Wang, Chinese University of Hong Kong (There are no in-person meetings.)). 2019-2021.</p>
Consulting / Honoraria	<p>Honorary Professor, National Research Center for Assisted Reproductive Technology and Reproductive Genetics, Shandong University, Jinan, China. 2012-Present</p> <p>Member, Steering Committee. Eastern Siberia PCOS Epidemiology &amp; Phenotype study, Scientific Center of Family Health and Human Reproduction, Irkutsk, Russian Federation. 2016 - present.</p> <p>Member, International Advisory Panel, Developing, disseminating and implementing a core outcome set for infertility. Funded by the Royal Society of New Zealand Catalyst Fund and the University of Auckland, New Zealand. 2017- present.</p> <p>Novo Nordisk. Consulting fees. Dec 2021 - present.</p> <p>Insudd. Consulting fees. 2020.</p>
Speakers' fees or honoraria	<p>Invited Webinar Speaker, Obesity and Women's Health Webinar: NIH Obesity Research Task Force (ORTF) Seminar Series. Sept 2020.</p>
Invited Webinar Speaker, Human Reproduction Update, Chinese Edition Young Editor Meeting.	<p>Apr 2020.</p>
Paid authorship	
Meeting attendance /paid expenses, e.g. travel, accomm, meals	
Intellectual Property (patents, licenses, royalties)	
Stock options / holdings	<p>Sharess in Biodesix (BDSX)</p>
Private practice or professional income	
Unpaid consultancies and/or in-kind support	
Family member employment/financial interests	
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg, professional organization)	<p>Fertility and Sterility. Editorial Editor, 2020-Present. Associate Editor, 2017-2020</p> <p>Global Reproductive Health. Associate Editor, 2017-Present</p> <p>Human Reproduction Update. Associate Editor, 2017-2020</p>
Relationship with organisations which advocate known industry or policy positions	<p>Endocrine Society. Member Investment Subcommittee, 2018-Present</p> <p>PCOS Challenge (patient support group). Member, Medical/Scientific Advisory Board, 2017-Present</p>
Relationships of Immediate family members	
Other	<p>NIH: ZHD1 DSR-K (LR) 1 Loan Repayment Program (Annually, 2008-Present), Special Emphasis Panel/Scientific Review Group 10 ZHD1 DSR-M (55): National Centers for Translational Research in Reproduction and Infertility (2020)</p>
Misc: Karolinska Institute, Stockholm, Sweden (2020)	
Additional information	
Are there any disclosures requiring a management plan?	No

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. Public funding sources, such as government agencies or academic institutions need not be disclosed. Time period for disclosure is within 3 years from when this form is completed.

[illegible]

## PCOS guideline advisory

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. [Public funding sources, such as](#)

Question	Ying Cheong	Cindy Farquhar	Sabrina Gill	Kristen Gill Hairston	Heather Huddleston	Rachel Morman	Robert Norman	Helena Teede
Research Grants / Contracts		Cochrane Innovations Fund. Obesity intervention evidence synthesis. 10,000 pounds for payment to individuals who did the work. This including time of critiquing the systematic reviews and guidelines and for ethics application and preparing and analysing the survey		No disclosures		No disclosures		No disclosures
Advisory boards		I was the senior editor for the Cochrane Abdomen:Endocrine Network for the first two years of the project. I received salary for that part of my role until December 2021. 2020-2021			Allara - Scientific Advisor 03/2020 - current		Ferring educational advice	
Consulting / Honoraria			Amgen, Pfizer, Bi. Advisory for diabetes, osteoporosis, thyroid. 2021-22					
Speakers' fees or honoraria	Merck, Nordic pharma		Amgen, Pfizer, Bi. Advisory for diabetes, osteoporosis, thyroid. 2021-22				Merck speaker 2020	
Paid authorship								
Meeting attendance /paid expenses, e.g. travel, accomm, meals								
Intellectual Property (patents, licenses, royalties)								
Stock options / holdings	Complete Fertility, Shareholder (minority)							
Private practice or professional income							Consultant REI training Flinders Fertility; Chair Clinical Advisory Committee Westmead fertility	
Unpaid consultancies and/or in-kind support							Panel for public IVF Victorian Government	
Family member employment/financial interests								
Relationship with organisations with financial links or affiliations with industry groups which stand to benefit from or may be affected by guideline recommendations (eg. professional organization)								
Relationship with organisations which advocate known industry or policy positions							Editorial Editor Fertility and Sterility	
Relationships of immediate family members								
Other								
Additional information								
Are there any disclosures requiring a management plan?	No	No	No	No	No	No	No	No

## PCOS guideline project management committee

Disclose support ONLY from entities that could be affected financially by the published work, such as drug companies, or foundations supported by entities that may have a financial stake in the outcome. **Public funding sources, such as government agencies or academic institutions need not be disclosed.** Time period for disclosure is within 3 years from when this form is completed.

[illegible]

Early/mid career network  
entities that could be affected  
financially by the published work,

[illegible]

Early/mid career network  
entities that could be affected  
financially by the published work.

[illegible]